Form 4: Mirum Pharmaceuticals CFO Sells Shares Under 10b5-1 Plan

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, has sold a total of 4,722 shares of common stock under a pre-arranged trading plan.

Summary

• Eric Bjerkholt, the Chief Financial Officer of Mirum Pharmaceuticals, Inc., reported the sale of common stock on July 6, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on March 9, 2026.
• A total of 4,722 shares were sold across four transactions.
• The sales occurred at weighted average prices ranging from $121.67 to $124.94 per share.
• Following these transactions, Mr. Bjerkholt beneficially owns 42,181 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a slightly negative sentiment due to the significant sale of shares by the CFO, despite the transaction being conducted under a pre-established 10b5-1 plan. This can create a perception of reduced insider confidence.

Negatives

• The Chief Financial Officer sold a significant number of shares (4,722) which could be perceived negatively by the market, despite being executed under a pre-planned 10b5-1 trading plan.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by the market as a lack of confidence in the company's near-term prospects, potentially impacting share price.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors. While these plans are designed to avoid accusations of insider trading by establishing a predetermined schedule for sales, they can still influence market perception. The pharmaceutical industry is highly sensitive to executive confidence, and significant sales by a CFO can sometimes lead to increased scrutiny.

Stakeholder Impact

• Shareholders: May view the CFO's sale as a potential negative signal, possibly leading to short-term share price pressure, even though it was executed under a pre-planned trading strategy.
• Employees: Similar to shareholders, employees with stock options or holdings may be concerned by the executive's decision to sell shares.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Key Dates

Recommendation

The filing reports a routine insider sale under a 10b5-1 plan, which is a standard disclosure. While such sales can sometimes create short-term negative sentiment, the pre-planned nature mitigates concerns about opportunistic trading. Without further financial performance data or strategic updates in this filing, a 'hold' recommendation is appropriate, suggesting investors monitor future disclosures for more substantive information.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Eric Bjerkholt, CFO, Beneficial Ownership